SOURCE: Eugene Science, Inc.

April 10, 2006 08:00 ET

Eugene Science Receives Initial CZ-S Order From Major Malaysian Food Supplement Distributor

Southeast Asian Distribution Partner to Build Product Awareness, Market Share

LOS ANGELES, CA -- (MARKET WIRE) -- April 10, 2006 -- Eugene Science, Inc. (OTC BB: EUSI), a developer and marketer of advanced nutraceutical products, today announced that Euro Chemo Pharma, a leading Malaysian food product distributor, has placed an initial order for its cholesterol-lowering CZ-S™ product.

Euro Chemo Pharma is one of Southeast Asia's leading distributors of quality nutritional supplements, food products and ingredients from numerous client companies including local and trans-national pharmaceutical, food and nutrition firms.

Euro Chemo Pharma is readying a strong marketing campaign for CZ-S™ that will ultimately include both water dispersible CZ-S™ and the oil dispersible CZ-SO™. These products may be infused to supplement select foods and beverages, and/or sold as a stand-alone nutraceutical consumer product. The companies anticipate further product sales or distribution agreements this summer.

"Malaysia is a thriving country of 24 million consumers, and Euro Chemo Pharma is ideally positioned to build brand value and market share for Eugene's CZ-S™ cholesterol-lowering product line," said Dr. Seung Kwon Noh, Chief Executive Officer, Eugene Sciences. "We are gratified at the strong early response CZ-S™ is generating from quality companies such as Euro Chemo Pharma, and are delighted to be able to help improve the heart health of millions of people worldwide."

While heart disease is often thought of as endemic to western industrialized countries, many developing countries such as Malaysia are experiencing escalating rates of heart disease. According to the World Health Organization, the age-standardized death rates from heart disease in Malaysia is 102 per 100,000 people, more than triple that of Japan's 33 and higher than Great Britain's 99. Another independent study found the incidence of high cholesterol in Malaysian male urban professionals nearly tripled from 12 percent to 31 percent over a ten-year period.

CZ-S™ is virtually taste-free, fully water-soluble and can be used in a wide variety of food products to lower cholesterol. It is composed of plant sterols that have been shown in clinical studies to lower cholesterol and that are approved by the United States Food and Drug Administration (FDA) for health claims related to their cholesterol-lowering efficacy.

About Euro Chemo Pharma

Headquartered in Penang, Malaysia, Euro Chemo Pharma was founded in 1975 and has its branch office and warehouse in Kuala Lumpur, Malaysia. The company also has laboratory and manufacturing facilities and its own trucking transportation system to maximize its distribution capability. With high quality product offerings, marketing and strong customer relationships, Euro Chemo Pharma is a leading supplier of products and ingredients to major food, pharmaceutical and cosmetic companies. For additional information, please visit Euro Chemo Pharma's website at www.eurochemo.com.

About Eugene Sciences

Eugene Science is a global biotechnology company focused on tackling ailments such as heart disease, obesity and diabetes though technological innovations and product developments in the nutraceutical field. As its first commercial heart disease product, Eugene Science has developed a nanoscience-based water soluble product called CZ™, a cholesterol-lowering functional food ingredient for health-conscious consumers, available in capsule form or as a food and beverage additive. Eugene Science intends to license its CZ™ line of cholesterol-lowering ingredients to companies worldwide. Eugene Science is headquartered in Bucheon, Kyunggi-Do, Korea, and was founded July 1997. For additional information, please visit Eugene Science's website at www.eugene21.com.

This press release includes certain "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995. These statements are based on Eugene Science's management's current expectations and are subject to risks, uncertainties and changes in circumstances. All forward-looking statements included in this press release are based upon information available to Eugene Science as of the date of the press release, and Eugene Science assumes no obligation to update or alter its forward-looking statements whether as a result of new information, future events or otherwise. These forward-looking statements may relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, and customer, consumer and other intentions, expectations and plans contained in this press release that are not historical fact. Further information on risks or other factors that could affect Eugene Science's results of operations is detailed in Eugene Science's filings with the United States Securities and Exchange Commission available at http://www.sec.gov.

Contact Information

  • Investor Relations Contact:
    Capital Group Communications
    Richard Carpenter or Mark Bernhard
    VP Investor Relations
    email: Email Contact
    (415) 332-7200